Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AlloVax (Immunovative Therapies)
- Development stage
- Unknown
- Lead developer
- Mirror Biologics
- Modality
- Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intratumoral, Intradermal, Intravenous
01
Overview
AlloVax is a personalized anti-cancer vaccine combination therapy developed by Immunovative Therapies. It consists of two primary components: **AlloStim**, an investigational living cell product comprising bioengineered allogeneic Th1-like immune cells derived from healthy donors, and **CRCL** (Chaperone Rich Cell Lysate), a personalized vaccine component derived from the patient's own tumor. AlloStim acts as a potent adjuvant by providing inflammatory "danger signals" through intentional mismatching with the patient's immune system, while CRCL provides a source of tumor-specific antigens and heat shock proteins (HSPs). The combination is designed to overcome tumor-induced immune suppression and stimulate a systemic, Th1-mediated anti-tumor immune response. It has been evaluated in clinical trials for advanced hepatocellular carcinoma and squamous cell carcinoma of the head and neck.
- Brand names
- AlloVax
- Other names
- AlloStim + CRCLAlloStim plus CRCLChaperone Rich Cell Lysate + AlloStim
Beyond the preview
Go deeper on AlloVax (Immunovative Therapies).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AlloVax (Immunovative Therapies).